Traditional approaches to virus detection– cell-based and in vivo assays - have served the biopharma industry very well over the years, but they have a long turn-around and do not identify specific contaminants. New molecular methods such as broad specificity degenerate PCR, and next generation sequencing (NGS) have been developed not only to replace or supplement traditional test methods but also expand the detection capabilities, thus expediting viral safety testing.
The Blazar™ platform provides researchers with accurate and highly sensitive viral detection in just days. Combining the breadth of detection of NGS with the speed and sensitivity of PCR, Blazar™ platform relies on degenerate PCR primers for coverage of more than 5000 viral variants. By amplifying multiple targets within a conserved region of the viral family genome, Blazar™ platform detects a much broader range of adventitious viruses as compared to traditional PCR methods.
 |
White paper: Rapid Biosafety testing enables the future of manufacturing |
This white paper explores the factors driving the evolution toward faster biosafety testing and describes rapid approaches for adventitious agent testing that are more aligned with manufacturing trends.
More Resources
Our expertise in NGS-based biosafety testing services allows us to provide complete solutions to our clients, from sample preparation and library generation through sequencing and data mining using state of the art computational and bioinformatics platforms, tools and methodologies. These results provide our clients with peace of mind, so they know that their test material is safe for biopharmaceucal production.
Blazar™ Rapid Molecular Platform
The Blazar™ rapid molecular platform is a viable alternative to in vitro detection assays.
